News and Trends 22 Aug 2019
Austrian Vaccine Developer Signs Deal with MSD in ‘Blockbuster Indication’
Vienna-based Themis Bioscience will develop vaccine candidates against an undisclosed disease target in partnership with big pharma Merck Sharp & Dohme. As part of the agreement, MSD will provide research funding and make an equity investment in Themis Bioscience. In addition, Themis will be eligible to receive up to €200M in milestones, in addition to […]